Ozone Therapy in Chemotherapy-induced Peripheral Neuropathy: RCT (O3NPIQ)

Recruiting Phase 2 Phase 3 Interventional Study
Chemotherapy-induced Peripheral Neuropathy Pain, Neuropathic Pain Syndrome
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 100
Sex
Any
Trial phase
Phase 2/3
Study type
Interventional
Purpose
Treatment
Participants needed
42 (estimated)
Sponsor
Bernardino Clavo, MD, PhD · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The main objective of this clinical trial is to evaluate the effectiveness and cost-effectiveness of adding ozone therapy to the clinical management of patients with pain secondary to chemotherapy-induced peripheral neuropathy

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * 1\. Adults \> = 18 years old. * 2\. Any kind of cancer in any stage, treated with any kind of chemotherapy, and life expectancy \> = 6 months. * 3\. Clinical diagnosis of painful chemotherapy-induced peripheral neuropathy, toxicity Grade 2 or higher according to the Common Tox…
Contacts

Bernardino Clavo, MD, PhD

(34)928449278

bernardinoclavo@gmail.com

CONTACT

Delvys Rodríguez-Abreu, MD

(34)928441779

drodabr@gobiernodecanarias.org

CONTACT